BioNTech SE announced on May 5, 2026 that it will eliminate up to 1,860 jobs, roughly 22% of its 8,455-person workforce, as it winds down Covid-19 vaccine manufacturing across Europe and Asia. The cuts span three German manufacturing sites in Idar-Oberstein, Marburg, and Tubingen, plus the company's Singapore operations. BioNTech said it is exploring partial or full sales of the affected facilities to avoid outright closures.
The German biotech reported Q1 2026 revenue of 118.1 million euros, down 35% year over year as Covid vaccine sales continued their post-pandemic decline. The company recorded a 605 million euro quarterly loss in the same period. BioNTech expects to wind down Singapore operations in Q1 2027 and exit the three German sites by the end of 2027.
BioNTech framed the cuts as a strategic redeployment of capital rather than a pure cost reduction. The company is targeting up to 500 million euros in annual savings, which it plans to redirect toward its oncology pipeline, including ongoing trials of mRNA-based cancer immunotherapies.
The pivot is not new. BioNTech has been signaling a multi-year transition away from Covid revenue dependence since 2024, but the May 2026 cuts mark the first time the company has put a hard headcount number on the restructuring. The 22% workforce reduction is the largest in BioNTech's history as a public company.
BioNTech is the third major Covid-era pharma name to formally scale back its pandemic-era manufacturing footprint in 2026, following Moderna and Pfizer. What distinguishes BioNTech's cut is the speed and the percentage. Cutting 22% of headcount in a single announcement is significantly faster than the multi-year, multi-tranche approach Moderna and Pfizer have used.
The deeper signal is the inversion of the 2020-2022 vaccine playbook. The same mRNA infrastructure that made BioNTech a $100 billion company is now stranded capacity. Capital that flowed into Covid production capability is being redirected into oncology bets that may not produce revenue for another five to seven years. For workers, that means German manufacturing science roles built specifically for a single vaccine class do not have an obvious internal landing spot.
Watch for two things from here. First, whether BioNTech can find buyers for the three German sites and the Singapore facility rather than closing them. Second, whether the oncology pipeline produces a near-term Phase 3 readout strong enough to justify the capital reallocation thesis to public-market shareholders.